Sweden's Senzime Q4 sales surge driven by hospital contracts, increased utilization rates

Senzime AB (publ)

18/02/2026 07:44

Overview

Sweden medical device firm's Q4 net sales rose 102% yr/yr

Gross margin affected by currency, US tariffs, and inventory write-downs

Company secured major agreements with NHS and Ivy League hospitals

Outlook

Senzime aims for profitability by end of 2026

Company targets positive cash-flow in Q4 2026

Senzime plans strong sales growth and stable operating expenses for 2026

Result Drivers

SALES GROWTH - Net sales increased by 102% in Q4, driven by hospital contracts and increased utilization rates among existing customers

GROSS MARGIN IMPACT - Gross margin affected by currency effects, US tariffs, and inventory write-downs

STRATEGIC DEALS - Secured major agreements with NHS and Ivy League hospitals, contributing to growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Miss
SEK 28.30 mln
SEK 31 mln (1 Analyst)
Q4 EPS
-SEK 0.27
Q4 Adjusted Gross Margin
25.10%


Analyst Coverage

Wall Street's median 12-month price target for Senzime AB (publ) is SEK12.00, about 172.1% above its February 17 closing price of SEK4.41

Press Release: ID:nMFN7pJpV6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)